[Oral treatment of severe psoriasis with a new aromatic retinoid (Ro 10-9359) (author's transl)].
The aromatic retinoic acid derivative Ro 10-9359 was administered orally to 25 severe psoriatic patients (14 with generalized plaques, 7 erythrodermic, 4 pustular). The initial dose was 25 mg/20 kg body weight daily for 4 weeks; afterwards the same posology was given every other day during several months (Max : 18 months). Excellent results were obtained in 16 patients (64 p. 100) particularly in severe erythrodermic and pustular psoriasis. However, under follow-up therapy relapses sometimes occurred leading to temporary resumption of initial posology. The most important side effects are cheilitis, palmoplantar scaling with thinning of the skin, hyperhidrosis and diffuse hair loss. A slight increase of transaminases and of alkaline phosphatases was found in a few patients. The Ro 10-9359 compound is a very useful new therapy of severe psoriasis.
D000284:Administration, Oral; D000328:Adult; D000469:Alkaline Phosphatase / Q000032:analysis; D000505:Alopecia / Q000139:chemically induced; D002613:Cheilitis / Q000139:chemically induced; D005260:Female; D006801:Humans; D006945:Hyperhidrosis / Q000139:chemically induced; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D000637:Transaminases / Q000032:analysis; D014212:Tretinoin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014801:Vitamin A / Q000031:analogs & derivatives*
D014801:Vitamin A; D014212:Tretinoin; D000637:Transaminases; D000469:Alkaline Phosphatase
Traitement oral des psoriasis graves par un nouveau rétinoide aromatique (Ro 10-9359).